ClinicalTrials.gg
CompletedNCT01614899Updated Apr 12, 2022Results posted

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

A Phase 3 interventional study of SM-13496 40mg and SM-13496 80mg in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
8th of 39
457 · median 149
Started
2012
with 4 others
Phase 3
18 of 39
none open now
Registered
22nd of 39
by date
Lead sponsor
3 of 39
Sumitomo Pharma Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 8th largest by enrollment, is one of 5 that started in 2012, is one of 18 in phase 3, and was the 22nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient meets criteria for schizophrenia.
  • Patient is aged 18 through 74 years at .
  • Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
  • Patient has Parkinson's disease.
  • Patient has a history or complication of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    SM-13496 40mg

    Drug: SM-13496 40mg

  • Experimental
    SM-13496 80mg

    Drug: SM-13496 80mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: Baseline and 6 week

Secondary outcomes

  1. Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6

    CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population

    Time frame: Baseline and 6 weeks

  2. Change From Baseline in PANSS Positive Subscale Scores at Week 6

    The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: Baseline and 6 weeks

  3. Change From Baseline in PANSS Negative Subscale Scores at Week 6

    The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: Baseline and 6 weeks

  4. Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6

    The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

    Time frame: Baseline and 6 weeks

  5. Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)

    Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.

    Time frame: From Baseline to 6 weeks

  6. Proportion of Participants With TEAEs Leading to Discontinuation

    Time frame: From Baseline to 6 weeks

  7. Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

    Time frame: From Baseline to 6 weeks

07

Results

Posted Oct 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Started150155152
Completed106116110
Not completed443942

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
Baseline and 6 week
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6-17.9 ± 1.72-17.3 ± 1.67-13.1 ± 1.72
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40mg vs Placebo · Mixed Model for Repeated Measures · p = 0.050 · Ls mean difference: -4.8 · 95% CI -9.52 to 0.00
  • SM-13496 (Lurasidone HCl) 80mg vs Placebo · Mixed Model for Repeated Measures · p = 0.080 · Ls mean difference: -4.2 · 95% CI -8.91 to 0.50
SecondaryChange From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6

CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6-0.86 ± 0.100-0.97 ± 0.097-0.79 ± 0.101
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40mg vs Placebo · Mixed Model for Repeated Measures · p = 0.594 · Ls mean difference: -0.08 · 95% CI -0.354 to 0.203
  • SM-13496 (Lurasidone HCl) 80mg vs Placebo · Mixed Model for Repeated Measures · p = 0.199 · Ls mean difference: -0.18 · 95% CI -0.453 to 0.095
SecondaryChange From Baseline in PANSS Positive Subscale Scores at Week 6

The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive Subscale Scores at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Change From Baseline in PANSS Positive Subscale Scores at Week 6-5.4 ± 0.54-6.2 ± 0.52-4.2 ± 0.54
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40mg vs Placebo · Mixed Model for Repeated Measures · p = 0.143 · Ls mean difference: -1.1 · 95% CI -2.60 to 0.38
  • SM-13496 (Lurasidone HCl) 80mg vs Placebo · Mixed Model for Repeated Measures · p = 0.010 · Ls mean difference: -1.9 · 95% CI -3.40 to -0.46
SecondaryChange From Baseline in PANSS Negative Subscale Scores at Week 6

The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Negative Subscale Scores at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Change From Baseline in PANSS Negative Subscale Scores at Week 6-3.9 ± 0.46-3.4 ± 0.45-2.9 ± 0.46
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40mg vs Placebo · Mixed Model for Repeated Measures · p = 0.116 · Ls mean difference: -1.0 · 95% CI -2.27 to 0.25
  • SM-13496 (Lurasidone HCl) 80mg vs Placebo · Mixed Model for Repeated Measures · p = 0.388 · Ls mean difference: -0.5 · 95% CI -1.80 to 0.70
SecondaryChange From Baseline in PANSS General Psychopathology Subscale Scores at Week 6

The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6-8.8 ± 0.85-7.9 ± 0.83-6.3 ± 0.85
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40mg vs Placebo · Mixed Model for Repeated Measures · p = 0.036 · Ls mean difference: -2.5 · 95% CI -4.87 to -0.17
  • SM-13496 (Lurasidone HCl) 80mg vs Placebo · Mixed Model for Repeated Measures · p = 0.174 · Ls mean difference: -1.6 · 95% CI -3.93 to 0.72
SecondaryProportion of Participants With Treatment-emergent Adverse Events (TEAEs)

Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.

Time frame:
From Baseline to 6 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)10310797
SecondaryProportion of Participants With TEAEs Leading to Discontinuation
Time frame:
From Baseline to 6 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With TEAEs Leading to Discontinuation
ParticipantsSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Proportion of Participants With TEAEs Leading to Discontinuation111116
SecondaryProportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

Time frame:
From Baseline to 6 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)433

Adverse events

Collected over From Baseline to 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SM-13496 (Lurasidone HCl) 40mg—4/150 (2.7%)99/150 (66%)
SM-13496 (Lurasidone HCl) 80mg—3/154 (1.9%)104/154 (67.5%)
Placebo—3/151 (2%)94/151 (62.3%)
Most frequent serious events
Most frequent serious events
EventSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
SchizophreniaPsychiatric disorders3/1503/1541/151
Psychotic disorderPsychiatric disorders1/1500/1540/151
Femoral neck fractureInjury, poisoning and procedural complications0/1500/1541/151
AnxietyPsychiatric disorders0/1500/1541/151
Most frequent other events
Showing 10 of 208
Most frequent other events
EventSM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlacebo
AkathisiaNervous system disorders11/15016/1545/151
HeadacheNervous system disorders14/1506/15412/151
ConstipationGastrointestinal disorders13/1505/15412/151
SchizophreniaPsychiatric disorders6/1506/15412/151
NauseaGastrointestinal disorders11/15012/1547/151
AnxietyPsychiatric disorders11/15011/1548/151
NasopharyngitisInfections and infestations9/15011/1547/151
InsomniaPsychiatric disorders10/15011/1546/151
VomitingGastrointestinal disorders9/1509/1543/151
SomnolenceNervous system disorders9/1504/1541/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)SM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlaceboTotal
Mean42.0 ± 13.143.6 ± 13.942.9 ± 13.542.9 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)SM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlaceboTotal
Female657358196
Male807984243
Region of Enrollment
Region of Enrollment(participants)SM-13496 (Lurasidone HCl) 40mgSM-13496 (Lurasidone HCl) 80mgPlaceboTotal
Japan626660188
Taiwan19211959
Korea, Republic of434243128
Malaysia21232064
08

Study locations

4 sites
  • 69 Sites
    Tokyo, Etc, Japan
  • 22 Sites
    Seoul, Etc, Korea, Republic of
  • 10 Sites
    Kuala Lumpur, Etc, Malaysia
  • 14 Sites
    Taipei, Etc, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jun 8, 2012
Start
Jul 2, 2012
Primary completionActual
Nov 17, 2014
CompletionActual
Nov 17, 2014
Results first posted
Oct 19, 2018
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01614899
Responsible party
Sponsor
First posted
Jun 8, 2012
Start date
Jul 2, 2012
Primary completion
Nov 17, 2014
Completion
Nov 17, 2014
Results posted
Oct 19, 2018
Last update
Apr 12, 2022

Study contacts

Clinical Development Drug development Division
study director · Sumitomo Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion